A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-02-15
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, placebo-controlled, randomized, phase II study to
investigate the efficacy and safety of Atezolizumab with or without Tiragolumab as
consolidation therapy in participants with limited stage small cell lung cancer who have not
progressed during/after chemoradiotherapy.